| Adverse effects of radioactive iodine-131 treatment for differentiated thyroid carcinoma A Fard-Esfahani, A Emami-Ardekani, B Fallahi, P Fard-Esfahani, D Beiki, ... Nuclear medicine communications 35 (8), 808-817, 2014 | 173 | 2014 |
| Low versus high radioiodine dose in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid carcinoma: a large randomized clinical trial B Fallahi, D Beiki, A Takavar, A Fard-Esfahani, KA Gilani, M Saghari, ... Nuclear medicine communications 33 (3), 275-282, 2012 | 114 | 2012 |
| Targeted delivery system based on gemcitabine-loaded silk fibroin nanoparticles for lung cancer therapy F Mottaghitalab, M Kiani, M Farokhi, SC Kundu, RL Reis, M Gholami, ... ACS applied materials & interfaces 9 (37), 31600-31611, 2017 | 96 | 2017 |
| Recent advances in the design and applications of amyloid-β peptide aggregation inhibitors for Alzheimer’s disease therapy S Jokar, S Khazaei, H Behnammanesh, A Shamloo, M Erfani, D Beiki, ... Biophysical reviews 11, 901-925, 2019 | 62 | 2019 |
| Does vitamin E protect salivary glands from I-131 radiation damage in patients with thyroid cancer? B Fallahi, D Beiki, SM Abedi, M Saghari, A Fard-Esfahani, F Akhzari, ... Nuclear Medicine Communications 34 (8), 777-786, 2013 | 59 | 2013 |
| The effect of high-dose radioiodine treatment on lacrimal gland function in patients with differentiated thyroid carcinoma A Fard-Esfahani, H Mirshekarpour, B Fallahi, M Eftekhari, M Saghari, ... Clinical Nuclear Medicine 32 (9), 696-699, 2007 | 54 | 2007 |
| 68Ga-radiolabeled bombesin-conjugated to trimethyl chitosan-coated superparamagnetic nanoparticles for molecular imaging: preparation, characterization and … M Hajiramezanali, F Atyabi, M Mosayebnia, M Akhlaghi, P Geramifar, ... International journal of nanomedicine, 2591-2605, 2019 | 53 | 2019 |
| Comparative evaluation of two fixed doses of 185 and 370 MBq 131I, for the treatment of Graves' disease resistant to antithyroid drugs. AF Esfahani, VR Kakhki, B Fallahi, M Eftekhari, D Beiki, M Saghari, ... Hellenic journal of nuclear medicine 8 (3), 158-161, 2005 | 50 | 2005 |
| Frequency and severity of myocardial perfusion abnormalities using Tc-99m MIBI SPECT in cardiac syndrome X M Saghari, M Assadi, M Eftekhari, M Yaghoubi, A Fard-Esfahani, ... BMC nuclear medicine 6, 1-8, 2006 | 49 | 2006 |
| Protective effects of hesperidin against genotoxicity induced by 99mTc-MIBI in human cultured lymphocyte cells SJ Hosseinimehr, A Ahmadi, D Beiki, E Habibi, A Mahmoudzadeh Nuclear medicine and biology 36 (7), 863-867, 2009 | 47 | 2009 |
| Synthesis and evaluation of [67Ga]-AMD3100: A novel imaging agent for targeting the chemokine receptor CXCR4 A Aghanejad, AR Jalilian, Y Fazaeli, B Alirezapoor, M Pouladi, D Beiki, ... Scientia Pharmaceutica 82 (1), 29, 2014 | 45 | 2014 |
| Preparation and Evaluation of 68Ga-ECC as a PET Renal Imaging Agent A Mirzaei, AR Jalilian, A Aghanejad, M Mazidi, H Yousefnia, G Shabani, ... Nuclear medicine and molecular imaging 49, 208-216, 2015 | 44 | 2015 |
| Diagnostic efficiency of 68Ga-DOTATATE PET/CT as compared to 99mTc-Octreotide SPECT/CT and conventional morphologic modalities in neuroendocrine tumors B Fallahi, R Manafi-Farid, M Eftekhari, A Fard-Esfahani, ... Asia Oceania Journal of Nuclear Medicine and Biology 7 (2), 129, 2019 | 42 | 2019 |
| Optimized production and quality control of 68Ga-DOTATATE A Aghanejad, AR Jalilian, S Maus, H Yousefnia, P Geramifar, D Beiki Iranian Journal of Nuclear Medicine 24 (1), 29, 2016 | 42 | 2016 |
| 99mtc-Ubiquicidin [29–41], a promising radiopharmaceutical to differentiate orthopedic implant infections from sterile inflammation D Beiki, G Yousefi, B Fallahi, MN Tahmasebi, A Gholamrezanezhad, ... Iranian journal of pharmaceutical research: IJPR 12 (2), 347, 2013 | 41 | 2013 |
| Radiosynthesis and biodistribution studies of [62Zn/62Cu]–plerixafor complex as a novel in vivo PET generator for chemokine receptor imaging A Aghanejad, AR Jalilian, Y Fazaeli, D Beiki, B Fateh, A Khalaj Journal of radioanalytical and nuclear chemistry 299, 1635-1644, 2014 | 39 | 2014 |
| 99mTc-PSMA SPECT/CT versus 68Ga-PSMA PET/CT in the evaluation of metastatic prostate cancer B Fallahi, N Khademi, N Karamzade-Ziarati, A Fard-Esfahani, ... Clinical Nuclear Medicine 46 (2), e68-e74, 2021 | 34 | 2021 |
| Evaluation of 99mTc-TRODAT-1 SPECT in the diagnosis of Parkinson’s disease versus other progressive movement disorders B Fallahi, A Esmaeili, D Beiki, S Oveisgharan, H Noorollahi-Moghaddam, ... Annals of nuclear medicine 30, 153-162, 2016 | 34 | 2016 |
| Radioiodine treatment complications to the mother and child in patients with differentiated thyroid carcinoma A Fard-Esfahani, M Hadifar, B Fallahi, D Beiki, M Eftekhari, M Saghari, ... Hell J Nucl Med 12 (1), 37-40, 2009 | 34 | 2009 |
| Design of peptide-based inhibitor agent against amyloid-β aggregation: Molecular docking, synthesis and in vitro evaluation S Jokar, M Erfani, O Bavi, S Khazaei, M Sharifzadeh, M Hajiramezanali, ... Bioorganic Chemistry 102, 104050, 2020 | 32 | 2020 |
Parham GeramifarMedical Physicist Specialist in Nuclear MedicineVerified email at tums.ac.ir
